Coherus Oncology (CHRS) Change in Receivables (2013 - 2026)

Coherus Oncology has disclosed Change in Receivables across 13 years of filings, most recently posting $4.3 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $4.3 million, up 108.41% year-over-year; the trailing twelve-month figure through Mar 2026 was -$38.4 million (up 79.97% YoY), and the FY2025 annual result was -$93.6 million, up 37.36% from the prior year.
• Change in Receivables came in at $4.3 million for Q1 2026 at Coherus Oncology, down from $8.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $75.3 million in Q3 2023 to a low of -$76.6 million in Q2 2024.
• The 5-year median for Change in Receivables is -$6.0 million (2022), against an average of -$5.9 million.
• Across the five-year window, Change in Receivables soared 3084.96% in 2023 and sank 493.2% in 2025, its largest moves.
• Coherus Oncology's Change in Receivables stood at $18.8 million in 2022, then jumped by 134.38% to $44.1 million in 2023, then sank by 227.85% to -$56.3 million in 2024, then surged by 114.8% to $8.3 million in 2025, then slumped by 48.64% to $4.3 million in 2026.
• The last three Change in Receivables figures came in at $4.3 million (Q1 2026), $8.3 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.